Here's Why HealthEquity (HQY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HQY - HealthEquity, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$107.43
DETAILS
HIGH:
$111.00
LOW:
$100.00
MEDIAN:
$108.00
CONSENSUS:
$107.43
UPSIDE:
13.00%
Stock News
GDRX or HQY: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why HealthEquity (HQY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY benefits from strong HSA growth, AI-driven automation and solid first-quarter fiscal 2027 results despite data security risks.
Is HealthEquity's Improving Profitability Enough to Offset Key Risks?
HQY raises fiscal 2027 guidance after strong Q1 results, but custodial yield swings and cybersecurity worries remain.
One in Three Americans Delay Medical Care Due to Cost, HealthEquity Research Finds
Healthcare Cost Pressures Drive Workplace Productivity Losses; HSA Holders Report Stronger Confidence and Control Healthcare Cost Pressures Drive Workplace Productivity Losses; HSA Holders Report Stronger Confidence and Control
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains.
3 Reasons Why Growth Investors Shouldn't Overlook HealthEquity (HQY)
HealthEquity (HQY) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts See a 33.49% Upside in HealthEquity (HQY): Can the Stock Really Move This High?
The consensus price target hints at a 33.5% upside potential for HealthEquity (HQY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why HealthEquity (HQY) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HealthEquity Stock Gains as Q1 Earnings Top Estimates, Revenues Up Y/Y
HQY tops Q1 FY27 EPS and revenue estimates as HSA accounts and assets climb, and guidance for FY27 revenues and adjusted EPS rises.
HealthEquity, Inc. (HQY) Q1 2027 Earnings Call Transcript
HealthEquity, Inc. (HQY) Q1 2027 Earnings Call Transcript
HealthEquity (HQY) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended April 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
A Look at HealthEquity Inc (HQY) After 4.6% Gain -- GF Value $101.45 vs Price $90.52
On May 28, 2026, HealthEquity Inc (HQY) shares rose by 4.6%, bringing the current price to $90.52. Over the past year, the stock has seen a 52-week range from a
HealthEquity (HQY) Q1 Earnings and Revenues Top Estimates
HealthEquity (HQY) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.97 per share a year ago.
HealthEquity Q1 Earnings Call Highlights
HealthEquity NASDAQ: HQY raised its fiscal 2027 outlook after reporting higher first-quarter profitability, record revenue in key categories and expanded margins, with management pointing to account growth, deeper member engagement and operating efficiencies from technology and artificial intelligence.
HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance
Increases Repurchase Program by $1.0 Billion Highlights of the first quarter include: Net income increased 29% to $69.4 million, and net income margin increased to 20% from 16% last year. Adjusted EBITDA increased 17% to $164.5 million, and Adjusted EBITDA margin increased to 46% from 42% last year.
The Triple Tax Free HSA Account High Earners Are Funding Before Maxing Their 401(k)
Picture a dual-income couple with combined wages well into the high six figures. They already max the 401(k). Their employer offers a high-deductible health plan, and they keep choosing the lower-premium PPO out of habit. That habit is costing them the most tax-advantaged account in the entire IRS code. The HSA is the only vehicle... The Triple Tax Free HSA Account High Earners Are Funding Before Maxing Their 401(k)
Price Targets
RBC Capital Reiterates Outperform Rating on HealthEquity, Inc (HQY) Following Mgmt Meet
$108.00
(was $88.34)
RBC Capital
HealthEquity, Inc (HQY) PT Raised to $111 at Citizens on Raised FY27-28 EPS Estimates
$111.00
(was $87.99)
Wells Fargo
HealthEquity upgraded to Outperform from Market Perform at BMO Capital
$105.00
(was $84.20)
Sean Dodge
·
BMO Capital
HealthEquity price target lowered to $85 from $100 at BMO Capital
$85.00
(was $74.78)
BMO Capital
HealthEquity price target lowered to $108 from $120 at Jefferies
$108.00
(was $78.77)
Jefferies
HealthEquity price target lowered to $110 from $118 at Barclays
$110.00
(was $74.36)
Peter Warendorf
·
Barclays
HealthEquity price target lowered to $110 from $130 at BTIG
$110.00
(was $73.88)
UBS
HealthEquity price target lowered to $100 from $120 at Raymond James
$100.00
(was $73.88)
Raymond James
HealthEquity downgraded to Sell from Neutral at Goldman Sachs
$89.00
(was $98.51)
Goldman Sachs
HealthEquity price target raised to $125 from $120 at KeyBanc
$125.00
(was $97.77)
Scott Schoenhaus
·
KeyBanc
HealthEquity initiated with an Overweight at Barclays
$118.00
(was $92.09)
Peter Warendorf
·
Barclays
HealthEquity price target raised to $120 from $117 at Deutsche Bank
$120.00
(was $95.12)
Deutsche Bank
HealthEquity price target raised to $122 from $117 at Citizens JMP
$122.00
(was $98.64)
JMP Securities
HealthEquity price target lowered to $120 from $125 at KeyBanc
$120.00
(was $88.50)
Scott Schoenhaus
·
KeyBanc
HealthEquity price target raised to $134 from $130 at Jefferies
$134.00
(was $95.54)
Glen Santangelo
·
Jefferies
HealthEquity price target lowered to $109 from $117 at RBC Capital
$109.00
(was $88.72)
Daniel Perlin
·
RBC Capital
HealthEquity Earns Stock Upgrade Despite Fraud Concerns
$115.00
(was $90.19)
Strong Buy
·
Raymond James
HealthEquity price target lowered to $110 from $120 at KeyBanc
$110.00
(was $90.32)
KeyBanc
HealthEquity price target lowered to $112 from $120 at Barrington
$112.00
(was $95.39)
Alexander Paris
·
Barrington
HealthEquity, Inc (HQY) PT Raised to $103 at Deutsche Bank
$103.00
(was $82.66)
George Hill
·
Deutsche Bank